MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
MESOBLAST LTD
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Aug 27, 2026
$11.95−1.33 (-10.02%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
70.2%
Net margin
-593.9%−351.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +191.4% | +19.0% | -11.8% | – | |
| Gross profit | +104.5% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | -11.2% | -14.1% | |
| Current ratio | – | 1.51 | 1.99 | |
| Capex to revenue | – | – | 4.0% | |
| Diluted shares | 364M | 529M | 1.21B |
Cash use needs five years of cash flow figures
Mesoblast does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$102.14M
- Cash generatingOperating cash flow above zero-$49.95M
- Return on assets improvedROA up on the prior year-13.1% → -15.3%
- Earnings backed by cashOperating cash flow above net income-$49.95M vs -$102.14M
- Less leverageLong-term debt to assets fell15.0% → 8.6%
- Better liquidityCurrent ratio rose1.18 → 1.99
- No dilutionShare count did not rise987M → 1.21B
- Gross margin improvedGross margin up on the prior year100.00% → 70.17%
- More efficientAsset turnover rose0.01 → 0.03